New CAR T-Cell combo shows promise against tough leukemia
NCT ID NCT06343090
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This study tests two different CAR T-cell therapy approaches for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. One group gets a combination of two types of CAR T-cells (CD19 and CD22), while the other gets one type (CD19) followed by a stem cell transplant. The goal is to see which approach helps patients live longer without the cancer returning. The trial is open to children and young adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.